Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of the Company’s pipeline of non-opioid pain treatment programs